Abstract
Ulerythema ophryogenes is a rare cutaneous atrophic disorder that occasionally is associated with Noonan syndrome, de Lange syndrome, Rubinstein-Taybi syndrome, and cardiofaciocutaneous (CFC) syndrome. Often presenting in pediatric patients, the pathogenesis of ulerythema ophryogenes remains unclear, though several genetic causes have been suggested. Treatment recommendations remain anecdotal, but clearance has been noted as the patient ages. Although topical agents have been the mainstay of therapy, recent advancement in laser intervention for treatment of ulerythema ophryogenes is promising.
MeSH terms
-
Abnormalities, Multiple / physiopathology*
-
Abnormalities, Multiple / therapy
-
Anti-Inflammatory Agents / therapeutic use
-
Child
-
Darier Disease / complications
-
Darier Disease / physiopathology*
-
Darier Disease / therapy
-
De Lange Syndrome / complications
-
Disease Progression
-
Ectodermal Dysplasia / complications
-
Eyebrows / abnormalities*
-
Eyebrows / physiopathology
-
Facies
-
Failure to Thrive / complications
-
Heart Defects, Congenital / complications
-
Humans
-
Intense Pulsed Light Therapy
-
Keratolytic Agents / therapeutic use
-
Lasers, Dye / therapeutic use
-
Low-Level Light Therapy
-
Noonan Syndrome / complications
-
Rubinstein-Taybi Syndrome / complications
-
Triamcinolone / therapeutic use
Substances
-
Anti-Inflammatory Agents
-
Keratolytic Agents
-
Triamcinolone
Supplementary concepts
-
Burnett Schwartz Berberian syndrome
-
Cardiofaciocutaneous syndrome